EP4566593A1 — A tablet comprising an extended-release formulation for metformin and immediate release formulation comprising sitagliptin
Assigned to Sanovel Ilac Sanayi ve Ticaret AS · Expires 2025-06-11 · 1y expired
What this patent protects
The present invention relates to a tablet formulation comprising a core tablet having metformin and microcrystalline cellulose, at least one matrix agent and a coating solution having sitagliptin surrounding the core tablet and a film coating wherein the coating solution further …
USPTO Abstract
The present invention relates to a tablet formulation comprising a core tablet having metformin and microcrystalline cellulose, at least one matrix agent and a coating solution having sitagliptin surrounding the core tablet and a film coating wherein the coating solution further comprises at least one antioxidant and at least one coating agent. Further, the present invention provides a method for the preparation of said composition.
Drugs covered by this patent
- Steglatro (ERTUGLIFLOZIN) · Merck & Co.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.